Program
Insulin Glargine
Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.
Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 1241 open or running | phase 4since Sep 9, 2005 | Sep 30, 2002 | none ahead |
| Novo Nordiskits history only | 280 open or running | phase 4since Sep 12, 2005 | Oct 29, 2004 | none ahead |
| Eli Lilly | 250 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Diabetes Care Centerits history only | 20 open or running | no phasesince Apr 3, 2007 | Apr 3, 2007 | none ahead |
| Biodelits history only | 10 open or running | phase 2since Oct 21, 2009 | Oct 21, 2009 | none ahead |
| Geropharmits history only | 10 open or running | no phasesince Sep 23, 2019 | Sep 23, 2019 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 3, 2009 | Sep 3, 2009 | none ahead |
| Wockhardtits history only | 10 open or running | phase 1since May 12, 2011 | May 12, 2011 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Sep 12, 2005.
- Aug 19, 20112 phase 3 studiesNCT01421459, NCT01421147
- Oct 5, 2011Phase 1 study in Diabetes MellitusNCT01476345 · 80 enrolled · South Africa
- May 15, 2012Phase 1 study in Diabetes Mellitus, Type 1NCT01600950 · 20 enrolled · Germany
- Jul 2, 2012Phase 1 study in Healthy VolunteersNCT01634165 · 24 enrolled · Singapore
- Sep 17, 2012Phase 1 study in HealthyNCT01688635 · 91 enrolled · Singapore
- May 5, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02132637 · 68 enrolled · United States, Germany
- Nov 25, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02302716 · 493 enrolled · United States, India, Korea, Republic of and more
- Nov 3, 2016Phase 1 study in HealthyNCT02955953 · 127 enrolled · Singapore
- Nov 7, 20172 phase 3 studiesNCT03338023, NCT03338010
- Jun 1, 2018Phase 1 study in HealthyNCT03555305 · 58 enrolled · China
- Nov 5, 2019Phase 4 study in Diabetes Mellitus, Type 2NCT04153981 · 304 enrolled · India
- Jul 10, 2020No phase study in Diabetes Mellitus, Type 1NCT04484779 · 67 enrolled · United States
- Apr 27, 2021Phase 4 study in Diabetes Mellitus, Type 2NCT04864977 · United States
- Jul 14, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05462756 · 730 enrolled · United States, Argentina, Germany and more
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 25 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05462756Diabetes Mellitus, Type 2 · United States, Argentina, Germany and more | 3 | Completed | Feb 27, 2024 | 730 |
| NCT04864977Diabetes Mellitus, Type 2 · United States | 4 | Withdrawn | Jun 6, 2022 | 0 |
| NCT04484779Diabetes Mellitus, Type 1 · United States | – | Completed | Dec 22, 2020 | 67 |
| NCT04153981Diabetes Mellitus, Type 2 · India | 4 | Completed | Jul 30, 2021 | 304 |
| NCT03555305Healthy · China | 1 | Completed | Nov 4, 2019 | 58 |
| NCT03338023Diabetes Mellitus, Type 1 · China | 3 | Completed | Mar 5, 2020 | 272 |
| NCT03338010Diabetes Mellitus, Type 2 · China | 3 | Completed | Mar 18, 2020 | 536 |
| NCT02955953Healthy · Singapore | 1 | Completed | Jan 4, 2017 | 127 |
| NCT02302716Diabetes Mellitus, Type 2 · United States, India, Korea, Republic of and more | 3 | Completed | Jul 2016 | 493 |
| NCT02132637Diabetes Mellitus, Type 2 · United States, Germany | 3 | Completed | Jul 2015 | 68 |
| NCT01688635Healthy · Singapore | 1 | Completed | Feb 2013 | 91 |
| NCT01634165Healthy Volunteers · Singapore | 1 | Completed | Sep 2012 | 24 |
| NCT01600950Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Jul 2012 | 20 |
| NCT01476345Diabetes Mellitus · South Africa | 1 | Completed | Jul 2012 | 80 |
| NCT01421459Diabetes Mellitus, Type 2 · United States, Czech Republic, France and more | 3 | Completed | Sep 2012 | 759 |
| NCT01421147Diabetes Mellitus, Type 1 · United States, Belgium, Germany and more | 3 | Completed | Aug 2012 | 536 |
| NCT01374178Diabetes Mellitus · Singapore | 1 | Completed | Jul 2011 | 16 |
| NCT01136746Hyperglycemia · United States | 3 | Terminated | Nov 2011 | 16 |
| NCT00560417Diabetes Mellitus, Type 2 · United States, Puerto Rico | 3 | Completed | Dec 2009 | 339 |
| NCT00551538Diabetes Mellitus, Type 2 · United States | 4 | Completed | 15 | |
| NCT00551356Diabetes Mellitus, Type 2 · Mexico | 3 | Completed | 53 | |
| NCT00437112Diabetes Mellitus, Type 2 · United States, Brazil, India and more | 3 | Completed | May 2008 | 142 |
| NCT00355849Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more | 3 | Completed | Jun 2008 | 555 |
| NCT00191464Diabetes Mellitus, Type 2 · United States, Australia, Greece and more | 4 | Completed | 320 | |
| NCT00191178Diabetes Mellitus, Type 2 · United States | 4 | Completed | 60 |
How it is read
Names in the registry
- “insulin glargine”, 38 entries
- “Insulin Glargine”, 27 entries
- “Insulin glargine”, 20 entries
- “INSULIN GLARGINE”, 15 entries
- “LY2963016”, 11 entries
Codes read as this program: HOE901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 124 studies
- Diabetes Mellitus, Type 1, 44 studies
- Diabetes Mellitus, 14 studies
- Hyperglycemia, 1 study
- Glucose Intolerance, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.